Advancements in risk stratification and management strategies in primary cardiovascular prevention

被引:4
|
作者
Barkas, Fotios [1 ]
Sener, Yusuf Ziya [2 ]
Golforoush, Pelin Arabacilar [3 ]
Kheirkhah, Azin [4 ]
Rodriguez-Sanchez, Elena [5 ,6 ]
Novak, Jan [7 ,8 ,9 ]
Apellaniz-Ruiz, Maria [10 ]
Akyea, Ralph Kwame [11 ]
Bianconi, Vanessa [12 ]
Ceasovschih, Alexandr [13 ]
Chee, Ying Jie [14 ]
Cherska, Mariia [15 ]
Chora, Joana Rita [16 ,17 ]
D'Oria, Mario [18 ]
Demikhova, Nadiia [19 ,20 ]
Burunkaya, Duygu Kocyigit [21 ]
Rimbert, Antoine [22 ]
Macchi, Chiara [23 ]
Rathod, Krishnaraj [24 ,25 ]
Roth, Lynn [26 ]
Sukhorukov, Vasily [27 ]
Stoica, Svetlana [28 ,29 ]
Scicali, Roberto [30 ]
Storozhenko, Tatyana [31 ,32 ]
Uzokov, Jamol [33 ]
Lupo, Maria Giovanna [34 ]
van der Vorst, Emiel P. C. [35 ,36 ,37 ,38 ]
Porsch, Florentina [39 ]
机构
[1] Univ Ioannina, Fac Med, Sch Hlth Sci, Dept Internal Med, Ioannina, Greece
[2] Hacettepe Univ, Fac Med, Dept Internal Med, Ankara, Turkiye
[3] UCL, Hatter Cardiovasc Inst, London, England
[4] Med Univ Innsbruck, Inst Genet Epidemiol, Innsbruck, Austria
[5] UCLA, Div Cardiol, Dept Med, Dept Physiol, Los Angeles, CA USA
[6] UCLA, Mol Biol Inst, Los Angeles, CA USA
[7] St Annes Univ Hosp Brno, Dept Internal Med 2, Brno, Czech Republic
[8] Masaryk Univ, Fac Med, Brno, Czech Republic
[9] Masaryk Univ, Fac Med, Dept Physiol, Brno, Czech Republic
[10] Univ Publ Navarra UPNA, Hosp Univ Navarra HUN, Navarra Inst Hlth Res IdiSNA, Genom Med Unit,Navarrabiomed, Pamplona, Spain
[11] Univ Nottingham, Ctr Acad Primary Care, Sch Med, Nottingham, England
[12] Univ Perugia, Dept Med & Surg, Perugia, Italy
[13] Grigore T Popa Univ Med & Pharm, Internal Med Dept, Iasi, Romania
[14] Tan Tock Seng Hosp, Dept Endocrinol, Singapore, Singapore
[15] Inst Endocrinol & Metab, Cardiol Dept, Kiev, Ukraine
[16] Inst Nacl Saude Doutor Ricardo Jorge, Dept Promocao Saude & Doencas Nao Transmissiveis, Unidade I&D, Grp Invest Cardiovasc, Lisbon, Portugal
[17] Univ Lisbon, BioISI Biosyst & Integrat Sci Inst, Fac Ciencias, Lisbon, Portugal
[18] Univ Trieste, Dept Med Surg & Hlth Sci, Div Vasc & Endovascular Surg, Trieste, Italy
[19] Sumy State Univ, Sumy, Ukraine
[20] Tallinn Univ Technol, Tallinn, Estonia
[21] Ankara Bilkent City Hosp, Cardiol Clin, Ankara, Turkiye
[22] Nantes Univ, Inst Thorax, CNRS, INSERM, Nantes, France
[23] Univ Milan, Dept Pharmacol & Biomol Sci Rodolfo Paoletti, Milan, Italy
[24] Queen Mary Univ London, William Harvey Res Inst, Ctr Cardiovasc Med & Devices, London, England
[25] St Bartholomews Hosp, Barts Heart Ctr, Barts Intervent Grp, London, England
[26] Univ Antwerp, Lab Physiopharmacol, Antwerp, Belgium
[27] Petrovsky Natl Res Ctr Surg, Lab Cellular & Mol Pathol Cardiovasc Syst, Moscow, Russia
[28] Victor Babes Univ Med & Pharm, Timisoara, Romania
[29] Inst Cardiovasc Dis Timisoara, Timisoara, Romania
[30] Univ Catania, Dept Clin & Expt Med, Catania, Italy
[31] Cardiovasc Ctr Aalst, OLV Clin, Aalst, Belgium
[32] LT Malaya Therapy Natl Inst NAMSU, Dept Prevent & Treatment Emergency Condit, Kharkiv, Ukraine
[33] Republican Specialized Sci Pract Med Ctr Therapy &, Tashkent, Uzbekistan
[34] Univ Padua, Dept Med, Padua, Italy
[35] Rhein Westfal TH Aachen, Inst Mol Cardiovasc Res IMCAR, D-52074 Aachen, Germany
[36] Rhein Westfal TH Aachen, Aachen Maastricht Inst CardioRenal Dis AMICARE, D-52074 Aachen, Germany
[37] Ludwig Maximilians Univ Munchen, Inst Cardiovasc Prevent IPEK, D-80336 Munich, Germany
[38] Rhein Westfal TH Aachen, Interdisciplinary Ctr Clin Res IZKF, D-52074 Aachen, Germany
[39] Med Univ Vienna, Dept Lab Med, Vienna, Austria
关键词
Cardiovascular disease; Atherosclerosis; Risk stratification; Plaque regression; Primary prevention; C-REACTIVE PROTEIN; CORONARY-ARTERY-DISEASE; COMPUTED-TOMOGRAPHY ANGIOGRAPHY; NORMAL BLOOD-PRESSURE; ANKLE-BRACHIAL INDEX; NF-KAPPA-B; SUBCLINICAL ATHEROSCLEROSIS; HEART-DISEASE; PLAQUE PROGRESSION; SECONDARY ANALYSIS;
D O I
10.1016/j.atherosclerosis.2024.117579
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality worldwide, highlighting the urgent need for advancements in risk assessment and management strategies. Although significant progress has been made recently, identifying and managing apparently healthy individuals at a higher risk of developing atherosclerosis and those with subclinical atherosclerosis still poses significant challenges. Traditional risk assessment tools have limitations in accurately predicting future events and fail to encompass the complexity of the atherosclerosis trajectory. In this review, we describe novel approaches in biomarkers, genetics, advanced imaging techniques, and artificial intelligence that have emerged to address this gap. Moreover, polygenic risk scores and imaging modalities such as coronary artery calcium scoring, and coronary computed tomography angiography offer promising avenues for enhancing primary cardiovascular risk stratification and personalised intervention strategies. On the other hand, interventions aiming against atherosclerosis development or promoting plaque regression have gained attention in primary ASCVD prevention. Therefore, the potential role of drugs like statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, omega -3 fatty acids, antihypertensive agents, as well as glucose -lowering and anti-inflammatory drugs are also discussed. Since findings regarding the efficacy of these interventions vary, further research is still required to elucidate their mechanisms of action, optimize treatment regimens, and determine their long-term effects on ASCVD outcomes. In conclusion, advancements in strategies addressing atherosclerosis prevention and plaque regression present promising avenues for enhancing primary ASCVD prevention through personalised approaches tailored to individual risk profiles. Nevertheless, ongoing research efforts are imperative to refine these strategies further and maximise their effectiveness in safeguarding cardiovascular health.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Aspirin for primary cardiovascular prevention: is there a need for risk stratification?
    Aimo, Alberto
    De Caterina, Raffaele
    EUROPEAN HEART JOURNAL, 2019, 40 (34) : 2922 - 2923
  • [2] Lipidomic Risk Score to Enhance Cardiovascular Risk Stratification for Primary Prevention
    Wu, Jingqin
    Giles, Corey
    Dakic, Aleksandar
    Beyene, Habtamu B.
    Huynh, Kevin
    Wang, Tingting
    Meikle, Thomas
    Olshansky, Gavriel
    Salim, Agus
    Duong, Thy
    Watts, Gerald F.
    Hung, Joseph
    Hui, Jennie
    Cadby, Gemma
    Beilby, John
    Blangero, John
    Moses, Eric K.
    Shaw, Jonathan E.
    Magliano, Dianna J.
    Zhu, Dantong
    Yang, Jean Y.
    Grieve, Stuart M.
    Wilson, Andrew
    Chow, Clara K.
    Vernon, Stephen T.
    Gray, Michael P.
    Figtree, Gemma A.
    Carrington, Melinda J.
    Inouye, Mike
    Marwick, Thomas H.
    Meikle, Peter J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (05) : 434 - 446
  • [3] CARRISMA: a new tool to improve risk stratification and guidance of patients in cardiovascular risk management in primary prevention
    Gohlke, Helmut
    Winter, Moritz
    Karoff, Marthin
    Held, Klaus
    EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2007, 14 (01): : 141 - 148
  • [4] Global Cardiovascular Risk Management in Primary Prevention
    Volpe, Massimo
    Tocci, Giuliano
    CURRENT VASCULAR PHARMACOLOGY, 2012, 10 (06) : 709 - 711
  • [5] Risk Stratification and Treatment of Obesity for Primary and Secondary Prevention of Cardiovascular Disease
    John W. Ostrominski
    Tiffany M. Powell-Wiley
    Current Atherosclerosis Reports, 2024, 26 : 11 - 23
  • [6] Risk Stratification and Treatment of Obesity for Primary and Secondary Prevention of Cardiovascular Disease
    Ostrominski, John W.
    Powell-Wiley, Tiffany M.
    CURRENT ATHEROSCLEROSIS REPORTS, 2024, 26 (01) : 11 - 23
  • [7] Risk stratification in secondary cardiovascular prevention
    Lazzeroni, Davide
    Coruzzi, Paolo
    MINERVA CARDIOANGIOLOGICA, 2018, 66 (04): : 471 - 476
  • [8] Dyslipidemia management in primary prevention of cardiovascular disease: Current guidelines and strategies
    Hendrani, Aditya D.
    Adesiyun, Tolulope
    Quispe, Renato
    Jones, Steven R.
    Stone, Neil J.
    Blumenthal, Roger S.
    Martin, Seth S.
    WORLD JOURNAL OF CARDIOLOGY, 2016, 8 (02): : 201 - 210
  • [9] Primary prevention strategies for cardiovascular disease
    Tyerman, G
    Tyerman, P
    Roscoe, TJ
    BRITISH MEDICAL JOURNAL, 2002, 325 (7370): : 969 - 969
  • [10] Effect of carotid atherosclerosis screening on risk stratification during primary cardiovascular disease prevention
    Bard, RL
    Kalsi, H
    Rubenfire, M
    Wakefield, T
    Fex, B
    Rajagopalan, S
    Brook, RD
    AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (08): : 1030 - 1032